1. Academic Validation
  2. Synthesis, Characterization, and Biological Evaluation of Novel Azo-Based Imidazo[1,2‑ a]pyridine Derivatives: In Vitro and In Silico Investigations

Synthesis, Characterization, and Biological Evaluation of Novel Azo-Based Imidazo[1,2‑ a]pyridine Derivatives: In Vitro and In Silico Investigations

  • ACS Omega. 2025 Nov 16;10(46):55842-55867. doi: 10.1021/acsomega.5c07351.
Mohamed Azzouzi 1 Salah Eddine El Hadad 2 Nawal Ikken 1 Sofia Fait 3 Mahelys Martine Ndjogo 3 M'hammed Chaoui Roqai 3 Mohammed Timinouni 3 Rachid Daoud 2 Adyl Oussaid 1
Affiliations

Affiliations

  • 1 Laboratory of Molecular Chemistry, Materials and Environment (LCM2E), Department of Chemistry, Multidisciplinary Faculty of Nador, University Mohammed First, 62700 Selouane, Nador, Morocco.
  • 2 Chemical and Biochemical Sciences, Green Process Engineering, University Mohammed VI Polytechnic, 43150 Ben Guerir, Morocco.
  • 3 Laboratoire de Biotechnologie et Bioinformatique. Ecole des Hautes Etudes de Biotechnologie et de santé (EHEB), 20250 Casablanca, Morocco.
Abstract

In this study, a series of azo-linked imidazo-[1,2-a]-pyridine derivatives (4a-f) was synthesized and fully characterized using FTIR, NMR (1H and 13C), and mass spectrometry. Structural and electronic properties were investigated through Density Functional Theory (DFT) at the B3LYP/6-311++G-(d,p) level, revealing key insights into charge distribution, molecular orbitals, and reactivity indices. The Antibacterial and antibiofilm activities were assessed in vitro against Gram-positive and Gram-negative strains, including multidrug-resistant isolates. 4e exhibited the most potent Antibacterial activity, with minimum inhibitory concentrations (MICs) of 0.5-1.0 mg/mL, and retained activity against resistant strains, showing MICs of 0.5-0.7 mg/mL against Escherichia coli CTXM and Klebsiella pneumoniae NDM. 4b and 4c notably inhibited biofilm formation at concentrations as low as 0.4 mg/mL against E. coli. Molecular docking studies indicated strong binding affinities for the active compounds, with 4b achieving the most favorable docking score (-10.4 kcal/mol) against the Bacterial target GyrB. These binding interactions were further corroborated by molecular dynamics simulations, which demonstrated stable protein-ligand complexes over a 100 ns trajectory with minimal structural deviations. Additionally, ADME-T and drug-likeness evaluations predicted favorable pharmacokinetic profiles for the majority of the compounds, highlighting their viability for further development. Overall, this study establishes azo-based imidazo-[1,2-a]-pyridine derivatives as promising scaffolds for future Antibacterial drug discovery.

Figures
Products